{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T13:20:10Z","timestamp":1788009610399,"version":"build-2784847793"},"reference-count":65,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["apjon.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pacific Journal of Oncology Nursing"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.apjon.2024.100579","type":"journal-article","created":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T05:19:05Z","timestamp":1724476745000},"page":"100579","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["CAR T-cell therapy in cancer: Integrating nursing perspectives for enhanced patient care"],"prefix":"10.1016","volume":"11","author":[{"given":"Ashna","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunjan","family":"Dagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd Umar","family":"Rehmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandra Prakash","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Saini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayank","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6491-0079","authenticated-orcid":false,"given":"Abhishek","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apjon.2024.100579_bib1","series-title":"Global Cancer Observatory: Cancer Today","year":"2022"},{"key":"10.1016\/j.apjon.2024.100579_bib2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-pathol-121808-102113","article-title":"Mutational heterogeneity in human cancers: origin and consequences","volume":"5","author":"Salk","year":"2010","journal-title":"Annu Rev Pathol"},{"issue":"3","key":"10.1016\/j.apjon.2024.100579_bib3","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.3390\/cancers3033279","article-title":"Assessment of the evolution of cancer treatment therapies","volume":"3","author":"Arruebo","year":"2011","journal-title":"Cancers"},{"key":"10.1016\/j.apjon.2024.100579_bib4","first-page":"3","article-title":"Immunological surveillance in neoplasia","volume":"7","author":"Burnet","year":"1971","journal-title":"Transplant Rev"},{"key":"10.1016\/j.apjon.2024.100579_bib5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s43152-023-00046-x","article-title":"Chimeric antigen receptor CAR-T therapy on the move: current applications and future possibilities","volume":"4","author":"Chakraborty","year":"2023","journal-title":"Curr Tissue Microenviron Rep"},{"key":"10.1016\/j.apjon.2024.100579_bib6","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0065-2776(06)90008-X","article-title":"Checkpoint blockade in cancer immunotherapy","volume":"90","author":"orman","year":"2006","journal-title":"Adv Immunol"},{"key":"10.1016\/j.apjon.2024.100579_bib7","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/s12967-023-04292-3","article-title":"Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments","volume":"21","author":"Dagar","year":"2023","journal-title":"J\u00a0Transl Med"},{"issue":"4877","key":"10.1016\/j.apjon.2024.100579_bib8","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1126\/science.3140379","article-title":"Single-chain antigen-binding proteins","volume":"242","author":"Bird","year":"1988","journal-title":"Science"},{"issue":"16","key":"10.1016\/j.apjon.2024.100579_bib9","doi-asserted-by":"crossref","first-page":"5879","DOI":"10.1073\/pnas.85.16.5879","article-title":"Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli","volume":"85","author":"Huston","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.apjon.2024.100579_bib10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/imr.12125","article-title":"Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma","volume":"257","author":"Chmielewski","year":"2014","journal-title":"Immunol Rev"},{"key":"10.1016\/j.apjon.2024.100579_bib11","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm.4478","article-title":"A\u00a0novel chimeric antigen receptor containing a JAK\u2013STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.apjon.2024.100579_bib12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s12254-021-00703-7","article-title":"CAR T cell therapy in solid tumors: a short review","volume":"14","author":"Umut","year":"2021","journal-title":"Memo"},{"key":"10.1016\/j.apjon.2024.100579_bib13","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.3390\/ijms22042150","article-title":"A\u00a0review of clinical outcomes of CAR T-cell therapies for B-acute lymphoblastic leukemia","volume":"22","author":"Martino","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apjon.2024.100579_bib14","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/leu.2015.311","article-title":"Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells","volume":"30","author":"Pinz","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.apjon.2024.100579_bib15","series-title":"Recent Updates on Chimeric Antigen Receptor T-Cell Approaches in Cancer Immunotherapy","author":"Sahlolbei","year":"2024"},{"key":"10.1016\/j.apjon.2024.100579_bib16","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1158\/2159-8290.CD-20-0242","article-title":"Surface proteomics reveals CD72 as a target for in vitro-evolved nanobody-based CAR-T cells in KMT2A\/MLL1-rearranged B-ALL","volume":"11","author":"Nix","year":"2021","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.apjon.2024.100579_bib17","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T therapies in multiple myeloma: unleashing the future","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.apjon.2024.100579_bib18","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T\u00a0cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"issue":"10 suppl l","key":"10.1016\/j.apjon.2024.100579_bib19","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.bulcan.2021.09.005","article-title":"CAR-T cells immunotherapy in multiple myeloma: present and future","volume":"108","author":"Ferment","year":"2021","journal-title":"Bull Cancer"},{"key":"10.1016\/j.apjon.2024.100579_bib20","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1158\/1078-0432.CCR-18-2559","article-title":"Combined CD28 and 4-1BB costimulation potentiates affinity-tuned chimeric antigen receptor-engineered T cells","volume":"25","author":"rent","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apjon.2024.100579_bib21","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, et\u00a0al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N."},{"key":"10.1016\/j.apjon.2024.100579_bib22","article-title":"Clinical activity and persistence of anti-CD22 chimeric antigen receptor in children and young adults with relapsed\/refractory acute lymphoblastic leukemia (ALL)","volume":"126","author":"Stetler-Stevenson","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.apjon.2024.100579_bib23","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40364-021-00309-5","article-title":"Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma","volume":"9","author":"Yin","year":"2021","journal-title":"Biomark Res"},{"key":"10.1016\/j.apjon.2024.100579_bib24","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1200\/JCO.23.02214","article-title":"Lisocabtagene Maraleucel in Relapsed\/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study","volume":"42","author":"Wang","year":"2024","journal-title":"JCO"},{"issue":"14","key":"10.1016\/j.apjon.2024.100579_bib25","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.apjon.2024.100579_bib26","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"17","key":"10.1016\/j.apjon.2024.100579_bib27","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1182\/blood-2011-10-387969","article-title":"CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results","volume":"119","author":"Till","year":"2012","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.apjon.2024.100579_bib28","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.apjon.2024.100579_bib29","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/blood.2019000905","article-title":"High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy","volume":"134","author":"Hirayama","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.apjon.2024.100579_bib30","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood.2023021243","article-title":"Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5)","volume":"143","author":"Neelapu","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.apjon.2024.100579_bib31","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.apjon.2024.100579_bib32","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.apjon.2024.100579_bib33","unstructured":"A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL). ClinicalTrials.gov identifier: NCT04245839. Updated August 2021. Accessed July 20, 2024. https:\/\/clinicaltrials.gov\/study\/NCT04245839."},{"issue":"7","key":"10.1016\/j.apjon.2024.100579_bib34","doi-asserted-by":"crossref","first-page":"6300","DOI":"10.3390\/ijms24076300","article-title":"CAR T cell therapy: a versatile living drug","volume":"24","author":"De Marco","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"20","key":"10.1016\/j.apjon.2024.100579_bib35","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.3390\/ijms20205010","article-title":"Resistance mechanisms to CAR T-cell therapy and overcoming strategy in B-cell hematologic malignancies","volume":"20","author":"Song","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.apjon.2024.100579_bib36","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.3390\/vaccines11111721","article-title":"CAR-T-Cell therapy in multiple myeloma: B-cell maturation antigen (BCMA) and beyond","volume":"11","author":"Mishra","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.apjon.2024.100579_bib37","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from car T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.apjon.2024.100579_bib38","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.apjon.2024.100579_bib39","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.apjon.2024.100579_bib40","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1038\/mt.2013.185","article-title":"Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma","volume":"21","author":"Hegde","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.apjon.2024.100579_bib41","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1158\/2159-8290.CD-15-1275","article-title":"Overcoming antigen escape with CAR T-cell therapy","volume":"5","author":"ackson","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.apjon.2024.100579_bib42","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.omto.2018.08.002","article-title":"Checkpoint blockade reverses anergy in IL-13R\u03b12 humanized scFv-based CAR T cells to treat murine and canine gliomas","volume":"11","author":"Yin","year":"2018","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.apjon.2024.100579_bib43","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1182\/blood-2018-99-112572","article-title":"Checkpoint inhibitors augment CD19-directed chimeric antigen receptor (CAR) T cell therapy in relapsed B-cell acute lymphoblastic leukemia","volume":"132","author":"Li","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.apjon.2024.100579_bib44","series-title":"Dominant-Negative TGF-\u03b2 Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation and Augments Prostate Cancer Eradication","author":"Kloss","year":"2018"},{"key":"10.1016\/j.apjon.2024.100579_bib45","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/imr.12125","article-title":"Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma","volume":"257","author":"hmielewski","year":"2014","journal-title":"Immunol Rev"},{"key":"10.1016\/j.apjon.2024.100579_bib46","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.apjon.2024.100579_bib47","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apjon.2024.100579_bib48","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"aude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apjon.2024.100579_bib49","series-title":"StatPearls [Internet]","article-title":"Chimeric Antigen Receptor T-Cell Therapy","author":"Zhang","year":"2022"},{"key":"10.1016\/j.apjon.2024.100579_bib50","first-page":"775","article-title":"Assessing and management of neurotoxicity after CAR-T therapy in diffuse large B-cell lymphoma","volume":"12","author":"Castaneda-Puglianini","year":"2021","journal-title":"J\u00a0Blood Med"},{"key":"10.1016\/j.apjon.2024.100579_bib51","series-title":"The EBMT\/EHA CAR-T Cell Handbook","article-title":"Management of immune effector cell-associated neurotoxicity syndrome (ICANS)","author":"Rees","year":"2022"},{"issue":"8","key":"10.1016\/j.apjon.2024.100579_bib52","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.ymthe.2017.04.024","article-title":"A\u00a0rational strategy for reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization","volume":"25","author":"Drent","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.apjon.2024.100579_bib53","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.3389\/fimmu.2020.01109","article-title":"CAR-T cells Hit the tumor microenvironment: strategies to overcome tumor escape","volume":"11","author":"Rodriguez-Garcia","year":"2020","journal-title":"Front Immunol"},{"issue":"9967","key":"10.1016\/j.apjon.2024.100579_bib54","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T\u00a0cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.apjon.2024.100579_bib55","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.apjon.2024.100579_bib56","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.apjon.2024.100579_bib57","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.apjon.2024.100579_bib58","first-page":"56","article-title":"Central nervous system infections in immunocompromised patients","volume":"31","author":"Castro","year":"2018","journal-title":"Rev Esp Quimioter"},{"issue":"1","key":"10.1016\/j.apjon.2024.100579_bib59","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.apjon.2024.100579_bib60","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.3390\/healthcare11131919","article-title":"Defining physician-nurse efforts toward collaboration as perceived by medical students","volume":"11","author":"Dahlawi","year":"2023","journal-title":"Healthcare (Basel)"},{"issue":"26","key":"10.1016\/j.apjon.2024.100579_bib61","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.apjon.2024.100579_bib62","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.apjon.2024.100579_bib63","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1183\/20734735.018016","article-title":"How to keep good clinical records","volume":"12","author":"Mathioudakis","year":"2016","journal-title":"Breathe"},{"issue":"1","key":"10.1016\/j.apjon.2024.100579_bib64","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.apjon.2021.12.007","article-title":"Development of management strategies for immune-related adverse effects of immunotherapies used in oncological treatment","volume":"9","author":"Shankar","year":"2021","journal-title":"Asia Pac J Oncol Nurs"},{"issue":"1","key":"10.1016\/j.apjon.2024.100579_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.31557\/APJCP.2023.24.1.1","article-title":"Operations management interventions in cancer care delivery in LMICs: the way forward","volume":"24","author":"Gautam","year":"2023","journal-title":"Asian Pac J Cancer Prev"}],"container-title":["Asia-Pacific Journal of Oncology Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2347562524002014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2347562524002014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,17]],"date-time":"2024-11-17T16:44:41Z","timestamp":1731861881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2347562524002014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":65,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2347562524002014"],"URL":"https:\/\/doi.org\/10.1016\/j.apjon.2024.100579","relation":{},"ISSN":["2347-5625"],"issn-type":[{"value":"2347-5625","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR T-cell therapy in cancer: Integrating nursing perspectives for enhanced patient care","name":"articletitle","label":"Article Title"},{"value":"Asia-Pacific Journal of Oncology Nursing","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apjon.2024.100579","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of Asian Oncology Nursing Society.","name":"copyright","label":"Copyright"}],"article-number":"100579"}}